1Zhao X, Drlica K. Restricting the selection of antibiotic - resistant mutants: a general strategy derived from fluoroquinolone studies[J].Clin Infect Dis, 2001, 33 (Suppl 3): 147-156.
2Zhao X, Drlica K. Restricting the selection of antibiotic - resistant mutant: measurement and potential uses of the mutant selection window[J].J Infect Dis, 2002, 185:561 -565.
3Drlica K. The mutant selection window and antimicrobial resistance [J]. J Antimicrob Chemother, 2003, 52:11-17.
4Firsov AA, Vostrov SN, Lubenko IY, et al. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against staphylococcus aureus [ J ].Antimicrob Agents Chemother, 2003, 47:1604 - 1613.
1[1]Drlica K. Antibiotic resistance: can we beat the bugs[J]? Drug Discov Today,2001;6: 714-6
2[2]Levy SB. Multidrug resistance: a sign of the times[J]. N Engl J Med,1998;38:1376-8
3[3]Zhao X. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolones studies[J]. Clin Infect Dis,2001;33:S147-56
4[4]Drlica K. A strategy for fighting antibiotic resistance[J]. ASM News, 2001;67:27-33
5[5]Drlica K. The future of fluoroquinolones[J]. Ann Med,2000;32:585-7
6[6]Dong Y, Zhao X, Domagala J, et al. Effect of fluoroquilonone concentration on selection of resistant mutants of mycobacterium bovis BCG and staphylococcus aureus[J]. Antimicro Agents Chemother,1999;43:1756-8
7[7]Dong Y, Zhao X, Kreiswirth BN, et al. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of mycobacterium tuberculosis [J]. Antimicrob Agents Chemother, 2000;44:2581-4
8[8]Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window[J]. J Infect Dis, 2002;185:561-5
9[9]Zhao J, Dong Y, Zhao X, et al. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquilonone-resistant mutantions[J]. J Infect Dis, 2002;182:517-25
10[10]Nakamura S. Mechanisms of quinolone resistance [J]. J Infect Chemother, 1997;3:128-38
5Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies [J]. Clin Infect Dis, 2001, 33(Suppl 3): 147-156.
6Clinical and Laboratory Standards lnstitute/NCCLS. Performance standards for antimicrobial susceptibility testing,Fifteenth informational supplement. CLSI/NCCLS document M100-S15 [M]. Wayne, Pennsylvania, Clinical and Laboratory Standards Institute, 2005, 25(1).
7Spiss H K, Kofler M, Hausdorfer H, et al. Streptococcus suis meningitis and neurophysiology of the acoustic system [J]. First case report from Austrial. Nervenarzt Aug. 1999, 70(8): 738-741.
8徐叔云.临床药理学[M].北京:人民卫生出版社,2004.112.
9Dong Y, Zhao X, Domagala J,et al. Effect of fluoroquilonone concentration on selection of resistant mutants of mycobacterium bovis BCG and staphylococcus aureus [J]. Antimicro Agents Chemother, 1999,43 : 1756-1758.
10Zhao X, Drlica K. Restricting the selection of antibiotic resistant mutant bacteria: measurement and potential use of the mutant selection window[J]. Infect Dis,2002,185 :561-565.
